AI Protein Design

AI protein design uses machine learning to create new proteins or reshape existing ones for specific jobs, such as binding a disease target, catalyzing a chemical reaction, or carrying genetic material into cells. Traditionally, researchers screened huge libraries by trial and error. Now they use generative models trained on protein sequences and structures to propose candidates computationally, then test the most promising ones in the lab. Many newer tools co-design sequence and three-dimensional structure together, aiming for molecules that fold as intended and behave predictably.

The field matters now because it is moving from academic demonstration toward commercial and clinical use. Large pharmaceutical companies are signing partnerships with AI-focused biotechs, and cloud providers are building dedicated infrastructure for drug discovery. Startups are raising capital to apply design methods to areas such as gene therapy delivery. AI-assisted drug programs are also advancing through clinical trials, which gives the industry its first real evidence of whether computational design shortens timelines or improves success rates. General-purpose AI developers and large technology companies are entering the space too, which widens the pool of people who can build and use these models.

On this page you'll find coverage of:

• New models and methods for generating, scoring, and co-designing proteins
• Pharma and biotech deals, including partnerships, licensing agreements, and funding rounds
• Applications spanning therapeutics, antibodies, engineered enzymes, and delivery vehicles
• Validation results, from lab hit rates to clinical trial milestones
• Infrastructure and platforms that make large-scale design and testing possible

This hub tracks how protein design is maturing from a promising technique into a working part of the discovery pipeline, for readers who follow drug development, synthetic biology, or AI research.